International journal of clinical practice
-
Int. J. Clin. Pract. · Apr 2011
Randomized Controlled TrialExtended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
In patients with primary hypercholesterolemia or mixed dyslipidemia, extended-release niacin/laropiprant (ERN/LRPT) improves key lipid parameters associated with increased atherosclerotic coronary heart disease (CHD) risk. ⋯ Extended-release niacin/laropiprant represents an effective therapeutic option for the treatment of dyslipidemia across a range of patient types.